Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.

Published in: European journal of haematology (2023)

PD-1 mab combined with Rituximab could be a potential treatment option for r/r DLBCL with manageable safety profile.

Keyphrases